Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Japan Staffers To Buy Out Research Lab From U.S. Parent (Japan)

This article was originally published in PharmAsia News

Executive Summary

Approximately 80 researchers at Pfizer's Aichi Prefecture laboratory plan to take over the operations and assets through an employee buyout. Pfizer is closing the laboratory, a decision that prompted the researchers to decide to establish a new-drug venture and buy facilities and the rights to develop substances for potential new drugs from Pfizer. The researchers will take a controlling stake in this venture in April 2008, with 10 billion yen to be raised from investment funds in Japan and abroad. The laboratory's director, Atsushi Nagahisa, is expected to be named president of the venture, which will likely go public in several years. Pfizer intends to accept the employee buyout, and may take a stake in the venture. (Click here for more - May Require Paid Subscription

You may also be interested in...

Pfizer Avoids Japan R&D Layoffs With Creation Of New Business

Pfizer is spinning off some of its Nagoya, Japan, research site into a venture-backed start-up called RaQualia Pharma Inc., the company reported July 3

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts